MX2018002816A - Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. - Google Patents

Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.

Info

Publication number
MX2018002816A
MX2018002816A MX2018002816A MX2018002816A MX2018002816A MX 2018002816 A MX2018002816 A MX 2018002816A MX 2018002816 A MX2018002816 A MX 2018002816A MX 2018002816 A MX2018002816 A MX 2018002816A MX 2018002816 A MX2018002816 A MX 2018002816A
Authority
MX
Mexico
Prior art keywords
methods
multiple myeloma
treating multiple
cell leukemia
plasma cell
Prior art date
Application number
MX2018002816A
Other languages
English (en)
Inventor
KOEHNE Guenther
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of MX2018002816A publication Critical patent/MX2018002816A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Abstract

Se describen en la presente métodos para tratar mieloma múltiple en un paciente humano que lo necesite, que comprenden administrar al paciente humano una población de células alogénicas que comprende células T alogénicas específicas de WT1. También se describen en la presente métodos para tratar leucemia de células plasmáticas en un paciente humano que lo necesite, que comprenden administrar al paciente humano una población de células alogénicas que comprende células T alogénicas específicas de WT1.
MX2018002816A 2015-09-10 2016-09-09 Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t. MX2018002816A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US201562220641P 2015-09-18 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
MX2018002816A true MX2018002816A (es) 2018-06-08

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018002816A MX2018002816A (es) 2015-09-10 2016-09-09 Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.

Country Status (14)

Country Link
US (1) US20190381098A1 (es)
EP (1) EP3347028A1 (es)
JP (1) JP6947720B2 (es)
KR (1) KR20180048992A (es)
CN (1) CN108348552A (es)
AU (1) AU2016320877A1 (es)
CA (1) CA2997757A1 (es)
HK (1) HK1257882A1 (es)
IL (1) IL257929B1 (es)
MX (1) MX2018002816A (es)
RU (1) RU2743381C2 (es)
TW (1) TWI759270B (es)
WO (1) WO2017044678A1 (es)
ZA (1) ZA201801656B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017415310B2 (en) 2017-05-25 2023-08-03 Memorial Sloan Kettering Cancer Center Use of the IL-15/IL-15Rα complex in the generation of antigen-specific T cells for adoptive immunotherapy
CA3074516A1 (en) 2017-10-23 2019-05-02 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1178956C (zh) * 1998-07-31 2004-12-08 杉山治夫 基于癌抑制基因wt1的产物的癌抗原
CA2349442C (en) * 1998-09-30 2012-12-04 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
ES2378264T3 (es) * 2003-11-05 2012-04-10 International Institute Of Cancer Immunology, Inc. Péptido antigénico de unión a HLA-DR derivado de WT1
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
RU2506311C2 (ru) * 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
WO2013106834A2 (en) * 2012-01-13 2013-07-18 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
JP2018530534A (ja) 2018-10-18
CA2997757A1 (en) 2017-03-16
ZA201801656B (en) 2022-12-21
RU2743381C2 (ru) 2021-02-17
WO2017044678A1 (en) 2017-03-16
CN108348552A (zh) 2018-07-31
RU2018112526A (ru) 2019-10-10
RU2018112526A3 (es) 2020-01-31
HK1257882A1 (zh) 2019-11-01
TW201714619A (zh) 2017-05-01
US20190381098A1 (en) 2019-12-19
AU2016320877A1 (en) 2018-04-19
IL257929A (en) 2018-05-31
IL257929B1 (en) 2024-02-01
JP6947720B2 (ja) 2021-10-13
EP3347028A1 (en) 2018-07-18
KR20180048992A (ko) 2018-05-10
TWI759270B (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
NZ765695A (en) Immune cell organoid co-cultures
PH12017500787A1 (en) Methods of selecting t cell line and donor thereof for adoptive cellular therapy
MX2019014009A (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
MX2021001878A (es) Metodos y composiciones para mejorar las celulas t reguladoras cd4+.
CA2956871C (en) Compounds active towards bromodomains
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
MX2018002816A (es) Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
NZ631701A (en) Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
NZ742327A (en) Neural cell extracellular vessicles
PH12017501993A1 (en) Methods of treating epstein-barr-virus-associated lymphoproliferative disorders by t cell therapy
MX365392B (es) Composición de combinación de pac-1 y doxorrubicina.
EP4275746A3 (en) Extracellular vesicles derived from osteoblastic lineage cells for therapeutic and diagnostic use
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX365403B (es) Peptidos y metodos para usarlos.
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
EP3998341A3 (en) Adenoviral vectors
MX2019013862A (es) Terapia de combinacion.
MX2019000677A (es) Células miméticas de células b.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
AU2018288712A1 (en) Methods for treating merkel cell carcinoma (MCC) using NK-92 cells
AR105142A1 (es) Métodos de tratamiento del glioblastoma multiforme con terapia de células t
AU2018250008B2 (en) Macro-encapsulated therapeutic cells and methods of using the same